NephroGenex — Investor Presentation (May 2016)
32 slides from NephroGenex's investor presentation, May 13, 2016
Slide 1: Corporate Presentation May 2016
Corporate Presentation May 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward- looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expe
Slide 3: Opportunity
Opportunity 3 NephroGenex, Inc., a specialty pharmaceutical Company that was focused on the development of therapeutics to treat kidney disease, determined based on financial considerations to pause its two key programs: 1) its phase 3 clinical program for oral Pyridorin for the treatment of diabe
Slide 4: NephroGenex Pipeline
NephroGenex Pipeline Clinical Program Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral dosing that targets the underlying metabolic pathophysiology of diabetic nephrop
Slide 5: Oral Pyridorin – Significant Market Potential
Oral Pyridorin – Significant Market Potential 5 Diabetic nephropathy progresses from microalbuminuria to macroalbuminuria, then to end stage renal disease (ESRD) and dialysis Estimated 31 million diabetics in the U.S. – 22 million diagnosed, 40% of whom exhibit kidney disease (France, Germany, and U
Slide 6: Pyridorin – Mechanism of Action
6 Pyridorin – Mechanism of Action
Slide 7: Clinical Overview: Ph2 Data in Target Ph3 Population
7 Clinical Overview: Ph2 Data in Target Ph3 Population (Type 2 Diabetes; SCr 1.3-3 mg/dL; Urinary Protein >1200 mg/g Cr; Stable SOC) PYR-210 (52 Wk PIVOTAL Ph 2b Study) PYR-206 PYR-205/207 (26 Wk Phase 2a Studies)
Slide 8: PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients
PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients 8
Slide 9: Preclinical and Clinical Safety
9 Preclinical No toxicity signal in multiple species: ― 13 - 100x human blood level in studies up to 12 months ― no signs of intolerance, toxicity or behavioral changes at doses of 50, 100 and 200 mg/kg in administered once daily through IV infusion for over 30 minutes for seven consecutive days
Slide 10: Overview of Phase 3 Study - PIONEER
Objective: Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population: Type 2 diabetic subjects Baseline SCr >1.3 and <3.0 mg/dL (eGFR > 20 ml/min) Protein/creat
Slide 11: Phase 3 Progress (April 30, 2016)
11 Phase 3 Progress (April 30, 2016) To date, 328 patients (out of 600) were enrolled during the first of two phase 3 trials required for approval (total of 1,200 patients) The study has successfully passed three DSMB reviews (2/21/21015; 7/29/2015; 1/21/2016) The study was halted due to finan
Slide 12: PYR-311 – Proposed Statistical Analysis
12 Review the statistical analysis plan with statistician prior to unblinding the data. Proposed data analysis to include: Mean change from baseline in SCr at 6 months, 9 months & 12 months: ― Pyridorin vs placebo ― ITT analysis Sensitivity analysis: ― Per-protocol analysis ― Impact of outliers
Slide 13: Oral Pyridorin (for DN) Exclusivity Patents and NCE
No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S. Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension) Method of manufacture patent February 2025 NCE - 5 year exclu
Slide 14: Acute Kidney Injury (AKI) and IV Pyridorin
Acute kidney injury (AKI) is a serious medical problem that results in substantial morbidity, prolonged hospitalization, increased medical costs, and significant mortality (AKI affects approximately 2.5 million U.S. hospitalized patients annually) The major causes of hospital-acquired AKI are de
Slide 15: AKI – Preclinical Ischemia-reperfusion Model
15 PYR treatment was provided to mice in drinking water starting 72 h prior to injury and continued until sacrificed. AKI – Preclinical/Ischemia-reperfusion (I/R) Model NF = nephrectomy
Slide 16: IV Pyridorin for AKI Exclusivity
16 Methods for treating or limiting development of AKI Patent Exclusivity Pending first U.S. non-provisional application that, if issued as a patent, would expire in October 2026 absent any patent term adjustment/extension Pending second family of applications with currently pending U.S. and PCT
Slide 17: Summary of Phase 2 Data
Summary of Phase 2 Data
Slide 18: Phase 2a Studies PYR-206 and PYR-205/207
PYR-206 (Safety & Tolerability Efficacy not pre-specified) PYR-205/7 (Dose Escalation) Phase 2a Studies - 26 Wk in Type 1 & 2 Diabetic Subjects With Mild/Moderate Nephropathy 18
Slide 19: Phase 2a Studies – Merged Dataset
19 Phase 2a Studies – Merged Dataset: PYR-206 & PYR205/207 Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB: Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy. Am J Nephrol 2007;27:605–614 SCr change fro
Slide 20: Pivotal Ph 2b Dose-Ranging Study in Type 2 Diabetic Subjects
20 Pivotal Ph 2b Dose-Ranging Study – 52 wks in Type 2 Diabetic Subjects with Overt Nephropathy (150 mg bd and 300 mg bd) Phase 3 study population agreed with FDA in the SPA
Slide 21: Importance of Stable Standard of Care in DN Trials
21 The FDA is aware of this observed effect of possible acute changes in SCr arising from ACEi/ARB/BP medication changes that could impact the SCr baseline and SCr-based calculated treatment effects. A pre-specified analysis was included in the Phase 2b Statistical Analysis Plan to evaluate the
Slide 22: Post-hoc Analysis of Phase 2b Endpoint
22 Post-hoc Analysis of Phase 3 Endpoint in Pivotal Ph 2b Study
Slide 23: Pyridorin Safety Profile: PYR-210
Pyridorin has a benign safety profile with the possible exception of a numerical increase in diarrhea and constipation with the higher dose of 300 mg BID Pyridorin Safety Profile: PYR-210 23 Most Reported Adverse Events Most Reported Serious Adverse Events No meaningful differences between groups
Slide 24: Appendix
Appendix
Slide 25: Serum Creatinine and eGFR Definitions
Definition Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Compar
Slide 26: PYR-206 – Phase 2a Study (50 mg BID)
26 PYR-206 – 24 Week Phase 2a Study (50 mg BID) PYR-206 Multi-center, randomized, double-blind, placebo- controlled trial to assess safety, tolerability and biological activity: N = 128 Population: Type 1 or type 2 diabetes ― Baseline SCr ≤ 2.0 mg/dL ― Urinary Protein: Creatinine Ratio (PCR) >30
Slide 27: Phase 2a PYR-206 Post-hoc Analysis
NephroGenex 6 Month Phase 2a PYR-206 Post-hoc Analysis Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Treatment Effect P value All Patients 65, 63 1.27 0.34 1.33 0.38 0.12 0
Slide 28: PYR-205/207 – Phase 2a Study (250 mg BID)
28 PYR-205/207 – 24 Week Phase 2a Study (250 mg BID) PYR-205/207 Multi-center, randomized, double- blind, dose-escalating, placebo- controlled trial to assess safety, tolerability and biological activity: N = 84 Population: Type 1 or type 2 diabetes ― SCr ≤ 2.0 mg/dL (PYR- 205); ― SCr >2 mg/dL a
Slide 29: Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis
NephroGenex 6 Month Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood pressure control Pyridorin at a 250 mg bid dose is well tolerated and slows
Slide 30: PYR-210 – Study Baseline Characteristics
30 PYR-210 – 52 Week Study - Baseline Characteristics
Slide 31: Phase 2b PYR-210 Pre-Specified Analysis: SOC vs. Non-SOC
NephroGenex 12 Month Phase 2b PYR-210 Pre-Specified Analysis: SOC at Screening vs. Non-SOC at Screening Patients analysis Type 2 Diabetic Nephropathy Patients With and Without SOC1 at screening – 300 and 150 mg bid 1 SOC: ACEI/ARB therapy and blood pressure control. Patients not on SOC at screening
Slide 32: Primary and Secondary Endpoints
Primary Endpoints: Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: ― A serum creatinine (SCr) increase of ≥50